safety of clinical trials.
CEO: Yesh Subramanian
Everist Genomics, Ann Arbor, MI: Developing diagnostics, prognostics, and therapeutic selection technologies for cancer and cardiovascular disease.
Chairman: Thomas Everist
Glycosensors and Diagnostics, Athens, GA: Provides enabling technologies for applications in glycoscience.
President: Robert Woods; Chief Scientific Officer; Lori Yang
Linnaeus Bioscience, San Diego: Developing a novel method for identifying and characterizing antibiotics.
Co-Founders: Joe and Kit Pogliano
Misfolding Diagnostics, San Diego: Researching biomarkers and companion diagnostics for protein amyloid diseases.
Leadership: Undisclosed
NeuroGeneration, Los Angeles, CA: Developing neural stem cell products targeting neurological disorders caused by cell loss or injury.
Founder & CEO: Michel F. Levesque
Neurolixis, San Diego: Developing small molecule compounds for treatment-resistant depression, and other CNS diseases and disorders.
Chief Scientific Officer: Adrian Newman-Tancredi
Renascions, San Diego: Working to improve clinical trial outcomes by optimizing patient recruitment, thereby potentially improving drug efficacy.
CEO: Henry Pan
Sialix, Inc., San Diego: Developing products for illnesses associated with non-human sialic acids.
CEO: Jeffrey Behrens
Silicon Biosystems, Bologna, Italy: Proprietary lab-on-a-chip technology to identify, manipulate, and sort specific cells within a heterogeneous population.
CEO: Giuseppe Giorgini
VLP Biotech, San Diego: Developing proprietary technologies to enhance T-cell response to vaccines.
Founder & CEO: Dave Milich; President: Yemi Onakunle
Wellspring Biosciences, San Diego: Discovering and developing small molecule drugs that target signal transduction networks.
CEO: Troy Wilson
Wibi+Works, LLC, New Orleans, LA: Developing uniform and predictable cell-based therapies for diseases associated with inflammation.
Founder and CSO: Aline M. Betancourt; CEO and Medical Director: Ruth S. Waterman
Yolia Health, Mexico City, Mexico: Developing a non-invasive treatment for presbyopia that improves vision by safely modifying the cornea.
Founder & CEO: Alberto Osio